Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Lymphoma, Large B-Cell, Diffuse 2Psoriasis 1Lymphoma, Mantle-Cell 1Lymphoma, Follicular 1Leukemia, Prolymphocytic 1Leukemia, Lymphocytic, Chronic, B-Cell 1Dermatitis 1

Interventions

fludarabine phosphate 40Cyclophosphamide 30Mycophenolic Acid 25Whole-Body Irradiation 23Peripheral Blood Stem Cell Transplantation 21Cyclosporine 17Tacrolimus 15Rituximab 15fludarabine 14Antilymphocyte Serum 14Busulfan 12Filgrastim 10Cyclosporins 10Methotrexate 8Sirolimus 7Therapeutics 6Melphalan 5Granulocyte Colony-Stimulating Factor 5Cytarabine 5Cord Blood Stem Cell Transplantation 5ibrutinib 4Psychiatric Rehabilitation 4Pharmacogenomic Testing 4Lenalidomide 4Carboplatin 4Allopurinol 4alvocidib 3Thiotepa 3Flow Cytometry 3Etoposide 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia, Prolymphocytic × sotrastaurin × Lymphoid × Clear all
NCT02285244 2017-04-05

Sotrastaurin Acetate in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, Prolymphocytic Leukemia, or Richter's Transformation

Ohio State University Comprehensive Cancer Center

Phase 2 Withdrawn
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Prolymphocytic, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡